首页> 外文期刊>Infection, Genetics and Evolution: Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases >Genetic diversity of G1P[8] rotavirus VP7 and VP8*antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq (R) vaccine
【24h】

Genetic diversity of G1P[8] rotavirus VP7 and VP8*antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq (R) vaccine

机译:芬兰20年来G1P [8]轮状病毒VP7和VP8 *抗原的遗传多样性:没有证据表明普遍采用RotaTeq(R)疫苗进行大规模疫苗接种会产生选择压力

获取原文
获取原文并翻译 | 示例
           

摘要

Two live-attenuated oral vaccines (Rotarix (TM) and Rotateq (R)) against rotavirus gastroenteritis were licensed in 2006 and have been introduced into National Immunization Programs (NIPs) of several countries. Large scale use of rotavirus vaccines might cause antigenic pressure on circulating rotavirus types or lead to selection of new rotaviruses thus decreasing vaccine efficacy. We examined the nucleotide and amino acid sequences of the surface proteins VP7 and VP4 (cleaved to VP8* and VP5*) of a total of 108 G1P[8] rotavirus strains collected over a 20-year period from 1992, including the years 2006-2009 when rotavirus vaccine (mainly Rotarix (TM)) was available, and the years 2009-2012 after implementation of RotaTeq (R) vaccine into the NIP of Finland. In G1 VP7 no changes at amino acid level were observed. In VP8* periodical fluctuation of the sublineage over the study period was found with multiple changes both at nucleotide and amino acid levels. Most amino acid changes were in the dominant antigenic epitopes of VP8*. A change in VP8* sublineage occurred between 2008 and 2009, with a temporal correlation to the use of Rotarix (TM) up to 30% coverage in the period. In contrast, no antigenic changes in the VP8* protein appeared to be correlated to the exclusive use of RotaTeq (R) vaccine after 2009. Nevertheless, long-term surveillance of antigenic changes in VP4 and also VP7 proteins in wild-type rotavirus strains is warranted in countries with large scale use of the currently licensed live oral rotavirus vaccines.
机译:两种针对轮状病毒胃肠炎的减毒活疫苗(Rotarix(TM)和Rotateq(R))已于2006年获得许可,并已被引入多个国家的国家免疫计划(NIP)。轮状病毒疫苗的大规模使用可能会对循环轮状病毒类型造成抗原压力或导致选择新的轮状病毒,从而降低疫苗效力。我们检查了从1992年起(包括2006年)的20年期间收集的总共108株G1P [8]轮状病毒株的表面蛋白VP7和VP4(裂解为VP8 *和VP5 *)的核苷酸和氨基酸序列2009年推出轮状病毒疫苗(主要是Rotarix(TM)),以及将RotaTeq(R)疫苗引入芬兰国家实施计划的2009-2012年。在G1 VP7中,未观察到氨基酸水平的变化。在VP8 *中,发现子系在研究期内的周期性波动在核苷酸和氨基酸水平上均发生了多次变化。大部分氨基酸变化都在VP8 *的优势抗原表位中。 VP8 *子系的变化在2008年至2009年之间发生,与Rotarix(TM)在此期间使用率高达30%的时间相关。相比之下,2009年之后,VP8 *蛋白的抗原变化似乎与独家使用RotaTeq(R)疫苗无关。然而,对野生型轮状病毒株中VP4和VP7蛋白的抗原变化进行长期监测是可行的。在大量使用当前许可的口服口服轮状病毒活疫苗的国家有保证。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号